A single oral 5 mg of duterium labeled methamphetamine
ApprovedWithdrawn 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Methamphetamine Metabolism, CYP2D6 Genotype
Conditions
Methamphetamine Metabolism, CYP2D6 Genotype
Trial Timeline
— → —
NCT ID
NCT01529892About A single oral 5 mg of duterium labeled methamphetamine
A single oral 5 mg of duterium labeled methamphetamine is a approved stage product being developed by Pacific Biosciences for Methamphetamine Metabolism, CYP2D6 Genotype. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01529892. Target conditions include Methamphetamine Metabolism, CYP2D6 Genotype.
Hype Score Breakdown
Clinical
30
Activity
20
Company
2
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01529892 | Approved | Withdrawn |
Competing Products
6 competing products in Methamphetamine Metabolism, CYP2D6 Genotype
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CPP-109 vigabatrin + Matching Placebo | Catalyst Pharmaceuticals | Phase 2 | 47 |
| Dextroamphetamine + Placebo | Pacific Biosciences | Phase 2 | 44 |
| modafinil | Pacific Biosciences | Phase 2 | 44 |
| Naltrexone | Pacific Biosciences | Phase 2 | 44 |
| Modafinil | Pacific Biosciences | Phase 2 | 44 |
| Ibudilast 20mg + Ibudilast 50mg + Placebo oral tablet | MediciNova | Phase 1 | 25 |